Dr. Colca has been involved in diabetes and related metabolic diseases research and drug development for his entire career. His postgraduate training in physiology and biochemistry was at the University of Houston and Washington University. He joined the Upjohn Company in 1984 and worked on the team that selected pioglitazone for development. He became leader of the Diabetes Project Team that took pioglitazone and other experimental drugs into clinical development. During this time he also led a large laboratory that had expertise in evaluating anti-diabetic therapeutics for efficacy, pharmacokinetics, and bioavailability. Dr. Colca co-founded MSDC with Dr. Rolf Kletzien in 2006 and is currently the President and CSO of MSDC. In this capacity, he has organized the ongoing development of two clinical candidates and helped lead studies that have identified the novel drug target, mTOTTM.